Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
24.55
-0.29 (-1.17%)
Streaming Delayed Price
Updated: 10:48 AM EDT, Jun 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
218,412
Open
24.93
Bid (Size)
24.55 (2)
Ask (Size)
24.60 (2)
Prev. Close
24.84
Today's Range
24.07 - 24.93
52wk Range
16.95 - 49.50
Shares Outstanding
79,199,501
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
June 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
June 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Performance
YTD
-10.43%
-10.43%
1 Month
+1.36%
+1.36%
3 Month
-27.71%
-27.71%
6 Month
-15.58%
-15.58%
1 Year
-23.33%
-23.33%
More News
Read More
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
May 30, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Expert Ratings For Beam Therapeutics
April 23, 2024
Via
Benzinga
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
March 27, 2024
Via
Benzinga
Navigating 4 Analyst Ratings For Beam Therapeutics
February 28, 2024
Via
Benzinga
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
May 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
Via
InvestorPlace
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
May 08, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Recap: Beam Therapeutics Q4 Earnings
February 27, 2024
Via
Benzinga
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
Via
InvestorPlace
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
May 07, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
April 12, 2024
Via
Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
Via
Benzinga
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
March 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
MarketBeat Week in Review – 3/4 – 3/8
March 09, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Via
MarketBeat
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
February 28, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Via
Investor's Business Daily
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Via
Investor's Business Daily
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Via
Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage Gain
February 27, 2024
Via
Investor Brand Network
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
February 27, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.